Mechanism of factor VIIa–dependent coagulation in hemophilia blood
- 1 February 2002
- journal article
- Published by American Society of Hematology in Blood
- Vol. 99 (3) , 923-930
- https://doi.org/10.1182/blood.v99.3.923
Abstract
The ability of factor VIIa to initiate thrombin generation and clot formation in blood from healthy donors, blood from patients with hemophilia A, and in anti-factor IX antibody-induced ("acquired") hemophilia B blood was investigated. In normal blood, both factor VIIa-tissue factor (TF) complex and factor VIIa alone initiated thrombin generation. The efficiency of factor VIIa was about 0.0001 that of the factor VIIa-TF complex. In congenital hemophilia A blood and "acquired" hemophilia B blood in vitro, addition of 10 to 50 nM factor VIIa (pharmacologic concentrations) corrected the clotting time at all TF concentrations tested (0-100 pM) but had little effect on thrombin generation. Fibrinopeptide release and insoluble clot formation were only marginally influenced by addition of factor VIIa. TF alone had a more pronounced effect on thrombin generation; an increase in TF from 0 to 100 pM increased the maximum thrombin level in "acquired" hemophilia B blood from 120 to 480 nM. Platelet activation was considerably enhanced by addition of factor VIIa to both hemophilia A blood and "acquired" hemophilia B blood. Thus, pharmacologic concentrations of factor VIIa cannot restore normal thrombin generation in hemophilia A and hemophilia B blood in vitro. The efficacy of factor VIIa (10-50 nM) in hemophilia blood is dependent on TF.Keywords
This publication has 59 references indexed in Scilit:
- Hepatitis, Epidemiology and Liver Function in Hemophiliacs in SwedenActa Medica Scandinavica, 2009
- Effects of HIV infection on age and cause of death for persons with hemophilia A in the United StatesAmerican Journal of Hematology, 2001
- Hemophilia ANew England Journal of Medicine, 1994
- Factor IX Concentrates for Clinical UseSeminars in Thrombosis and Hemostasis, 1993
- Heterogeneity of human factor V deficiency. Evidence for the existence of antigen-positive variantsJournal of Clinical Investigation, 1983
- Characterization of the human factor VIII procoagulant protein with a heterologous precipitating antibody.Proceedings of the National Academy of Sciences, 1982
- Factor VII deficiencyAmerican Journal of Hematology, 1981
- Acquired Factor IX DeficiencyActa Haematologica, 1973
- Evaluation of a New Concentrate for the Treatment of Factor IX DeficiencyNew England Journal of Medicine, 1969
- A CONCENTRATE OF HUMAN ANTIHÆMOPHILIC FACTOR: ITS USE IN SIX CASES OF HÆMOPHILIAThe Lancet, 1957